Akademik Veri Yönetim Sistemi
35th European Congress of Pathology, Dublin, İrlanda, 9 - 13 Eylül 2023, ss.26
Background & objectives
Gleason scores guide clinical management in prostate adenocarcinoma. Cribriform glands are
linked to poorer outcomes. Our study aims to assess the prognostic role of invasive cribriform
gland size and percentage in low-intermediate risk group adenocarcinomas.
Methods
Our study enrolled 177 male patients with Grade Group 2 and 3 prostate adenocarcinoma. All
cases were re-evaluated and recorded clinical and pathological data. The largest invasive
cribriform gland was identified and its diameter measured. P63 was used as a basal marker
for all cases
Results
The mean age of the patients was 67.8 years. Lymph node metastasis was not detected in
cases without cribriform pattern, whereas it was noted in 22.5% of cases with cribriform pattern
(p=0.014). The mean percentage of cribriform glands and the mean largest invasive cribriform
gland size were significantly higher in cases with lymph node metastasis compared to cases
without lymph node metastasis (34.3% - 2.98 mm vs. 17.5% - 1.98 mm, respectively; p<0.001
and p=0.003, respectively). Biochemical recurrence-free survival was significantly lower in
cases with a maximum invasive cribriform gland diameter of >0.5 mm (p<0.001) and in cases
with a cribriform pattern percentage of >10% (p<0.001).
Conclusion
Mean cribriform gland sizes and percentages were significantly associated with more
advanced pT status, a higher rate of extraprostatic extension, lymph node metastasis,
biochemical recurrence, higher preoperative PSA values, surgical margin positivity, and lower
biochemical recurrence-free survival. Our findings suggest that a more aggressive clinical
approach may be needed in grade group 2 and 3 cases with invasive cribriform glands larger
than 0.5 mm and a cribriform gland percentage of >10% in prostate needle biopsies.